← Back to Search

Herbal Medicine

T89 for Altitude Sickness

Phase 3
Waitlist Available
Led By Jeffrey W Sall, PhD, MD
Research Sponsored by Tasly Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Healthy volunteers: ages 18 - 55 years old
Be between 18 and 65 years old
Must not have
Subjects with current and clinically significant respiratory system disease, digestive disease, liver disease, central nervous system disease, psychiatric disease, metabolic disease, renal disease, acute infection or anemia, or who test positive for COVID-19 (COVID testing will be performed, not per study requirement, but in compliance with local law or policy, and subject with known positive for COVID-19 will be excluded)
Contradictive to treatment of Danshen (Radix Saliva Miltiorrhize Bge., RSM) products
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 4-5
Awards & highlights

Summary

This trial tests T89, a herbal pill, to see if it can prevent or reduce symptoms of Acute Mountain Sickness in people going to high altitudes. The pill helps the body handle low oxygen levels better. T89 (Dantonic) is a modern herbal medicine currently used in Chinese hospitals for the management of heart disease.

Who is the study for?
Healthy adults aged 18-55, living below 2,461 ft elevation, who haven't been to high altitudes recently. Women must test negative for pregnancy and use contraception. Excludes those with recent headaches, abnormal blood tests, on certain meds or supplements (except birth control), smokers, substance abusers, and anyone with significant health issues.
What is being tested?
This phase III trial is testing T89 capsules against placebo to see if they can prevent or relieve symptoms of Acute Mountain Sickness after quickly going up in altitude. Participants are randomly assigned to either the T89 treatment or a dummy pill without knowing which one they're getting.
What are the potential side effects?
While the trial primarily aims to assess safety and efficacy of T89 for Altitude Sickness prevention and symptom relief, potential side effects are not detailed here but will be monitored throughout the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 55 years old and healthy.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have significant health issues like lung, liver, kidney diseases, or COVID-19.
Select...
I cannot take Danshen products due to adverse reactions.
Select...
My liver or kidney tests are not normal.
Select...
I have a history of heart, stroke, or asthma issues, or my blood pressure is often above 140/90.
Select...
I have not had surgery or donated blood in the last 3 months.
Select...
I am not pregnant or breastfeeding.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 4-5
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 4-5 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change of baseline corrected mean LLSS score on Day 4 morning (next mornings after arrival at high altitude) between T89 and placebo groups.
Secondary study objectives
Accumulated incidence rate of subjects who underwent any rescue activity in transit and after ascending between T89 and placebo groups.
The change in total incidence of LLSS score ≥5 on Day 4 morning between T89 and placebo groups.
The change of baseline corrected LLSS score at any given time points between T89 and placebo groups.
+8 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: T89 low-dose groupExperimental Treatment2 Interventions
Subjects in this group will take three T89 capsules and one Placebo capsule each time by oral administration three times daily for 5 days.
Group II: T89 high-dose groupExperimental Treatment1 Intervention
Subjects in this group will take four T89 capsules each time by oral administration three times daily for 5 days.
Group III: Placebo groupPlacebo Group1 Intervention
Placebo capsule does not contain any amount of active substance. Subjects in this group will take four placebo capsules each time by oral administration three times daily for 5 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
T89 capsule
2018
Completed Phase 3
~990
Placebo capsule
2015
Completed Phase 4
~5270

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for altitude sickness include acetazolamide, dexamethasone, and supplemental oxygen. Acetazolamide induces mild metabolic acidosis, stimulating breathing and improving oxygenation. Dexamethasone reduces inflammation and cerebral edema. Supplemental oxygen increases the amount of oxygen available to the body. These treatments are essential for altitude sickness patients as they address the primary issue of inadequate oxygen supply, preventing severe complications such as high-altitude cerebral edema (HACE) and high-altitude pulmonary edema (HAPE).
Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice.Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.Should homeopathy be considered as part of a treatment strategy for otitis media with effusion in children?

Find a Location

Who is running the clinical trial?

Tasly Pharmaceuticals, Inc.Lead Sponsor
22 Previous Clinical Trials
4,729 Total Patients Enrolled
2 Trials studying Altitude Sickness
190 Patients Enrolled for Altitude Sickness
Jeffrey W Sall, PhD, MDPrincipal InvestigatorDepartment of Anesthesia and Perioperative Care, University of California, San Francisco, CA, U.S.
1 Previous Clinical Trials
132 Total Patients Enrolled
1 Trials studying Altitude Sickness
132 Patients Enrolled for Altitude Sickness
Henry H Sun, PhD, MDStudy ChairTasly Pharmaceuticals, Inc.
1 Previous Clinical Trials
765 Total Patients Enrolled

Media Library

T89 (Herbal Medicine) Clinical Trial Eligibility Overview. Trial Name: NCT04993729 — Phase 3
Altitude Sickness Research Study Groups: T89 low-dose group, T89 high-dose group, Placebo group
Altitude Sickness Clinical Trial 2023: T89 Highlights & Side Effects. Trial Name: NCT04993729 — Phase 3
T89 (Herbal Medicine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04993729 — Phase 3
~205 spots leftby Oct 2025